Viatris Inc. (Nasdaq: VTRS) announced positive top-line results from a Phase 3 clinical trial of VR-205, a targeted-release budesonide formulation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE